Serum globotriaosylceramide assay as a screening test for Fabry disease in patients with ESRD on maintenance dialysis in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, J.-Y. | - |
dc.contributor.author | Hyun, Y.-Y. | - |
dc.contributor.author | Lee, J.-E. | - |
dc.contributor.author | Yoon, H.-R. | - |
dc.contributor.author | Kim, G.-H. | - |
dc.contributor.author | Yoo, H.-W. | - |
dc.contributor.author | Cho, S.-T. | - |
dc.contributor.author | Chun, N.-W. | - |
dc.contributor.author | Jeoung, B.-C. | - |
dc.contributor.author | Kim, H.-J. | - |
dc.contributor.author | Kim, K.-W. | - |
dc.contributor.author | Kim, S.-N. | - |
dc.contributor.author | Kim, Y.-A. | - |
dc.contributor.author | Lee, H.-A. | - |
dc.contributor.author | Lee, J.-Y. | - |
dc.contributor.author | Lee, Y.-C. | - |
dc.contributor.author | Lim, H.-K. | - |
dc.contributor.author | Oh, K.-S. | - |
dc.contributor.author | Son, S.-H. | - |
dc.contributor.author | Yu, B.-H. | - |
dc.contributor.author | Wee, K.-S. | - |
dc.contributor.author | Lee, E.-J. | - |
dc.contributor.author | Lee, Y.-K. | - |
dc.contributor.author | Noh, J.-W. | - |
dc.contributor.author | Kim, S.-J. | - |
dc.contributor.author | Choi, K.-B. | - |
dc.contributor.author | Yu, S.-H. | - |
dc.contributor.author | Pyo, H.-J. | - |
dc.contributor.author | Kwon, Y.-J. | - |
dc.date.accessioned | 2021-09-08T09:04:23Z | - |
dc.date.available | 2021-09-08T09:04:23Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/118264 | - |
dc.description.abstract | Background/Aims: Fabry disease is an X-linked recessive and progressive disease caused by α-galactosidase A (α-GaL A) deficiency. We sought to assess the prevalence of unrecognized Fabry disease in dialysis-dependent patients and the efficacy of serum globotriaosylceramide (GL3) screening. Methods: A total of 480 patients of 1,230 patients among 17 clinics were enrolled. Serum GL3 levels were measured by tandem mass spectrometry. Additionally, we studied the association between increased GL3 levels and cardiovascular disease, cerebrovascular disease, or left ventricular hypertrophy. Results: Twenty-nine patients had elevated serum GL3 levels. The α-GaL A activity was determined for the 26 patients with high GL3 levels. The mean α-GaL A activity was 64.6 nmol/hr/mg (reference range, 45 to 85), and no patient was identified with decreased α-GaL A activity. Among the group with high GL3 levels, 15 women had a α- GaL A genetics analysis. No point mutations were discovered among the women with high GL3 levels. No correlation was observed between serum GL3 levels and α-GaL A activity; the Pearson correlation coefficient was 0.01352 (p = 0.9478). No significant correlation was observed between increased GL3 levels and the frequency of cardiovascular disease or cerebrovascular disease. Conclusions: Fabry disease is very rare disease in patients with end-stage renal disease. Serum GL3 measurements as a screening method for Fabry disease showed a high false-positive rate. Thus, serum GL3 levels determined by tandem mass spectrometry may not be useful as a screening method for Fabry disease in patients with end stage renal disease. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.subject | alpha galactosidase | - |
dc.subject | globotriaosylceramide | - |
dc.subject | adult | - |
dc.subject | article | - |
dc.subject | cerebrovascular disease | - |
dc.subject | clinical article | - |
dc.subject | controlled study | - |
dc.subject | diagnostic accuracy | - |
dc.subject | disease association | - |
dc.subject | enzyme activity | - |
dc.subject | Fabry disease | - |
dc.subject | female | - |
dc.subject | heart left ventricle hypertrophy | - |
dc.subject | hemodialysis | - |
dc.subject | human | - |
dc.subject | kidney failure | - |
dc.subject | Korea | - |
dc.subject | maintenance therapy | - |
dc.subject | male | - |
dc.subject | mutational analysis | - |
dc.subject | patient assessment | - |
dc.subject | protein blood level | - |
dc.subject | screening test | - |
dc.subject | tandem mass spectrometry | - |
dc.subject | Adult | - |
dc.subject | Aged | - |
dc.subject | alpha-Galactosidase | - |
dc.subject | Fabry Disease | - |
dc.subject | Female | - |
dc.subject | Humans | - |
dc.subject | Kidney Failure, Chronic | - |
dc.subject | Male | - |
dc.subject | Middle Aged | - |
dc.subject | Renal Dialysis | - |
dc.subject | Trihexosylceramides | - |
dc.title | Serum globotriaosylceramide assay as a screening test for Fabry disease in patients with ESRD on maintenance dialysis in Korea | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Pyo, H.-J. | - |
dc.contributor.affiliatedAuthor | Kwon, Y.-J. | - |
dc.identifier.doi | 10.3904/kjim.2010.25.4.415 | - |
dc.identifier.scopusid | 2-s2.0-78650971082 | - |
dc.identifier.bibliographicCitation | Korean Journal of Internal Medicine, v.25, no.4, pp.415 - 421 | - |
dc.relation.isPartOf | Korean Journal of Internal Medicine | - |
dc.citation.title | Korean Journal of Internal Medicine | - |
dc.citation.volume | 25 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 415 | - |
dc.citation.endPage | 421 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001498779 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | alpha galactosidase | - |
dc.subject.keywordPlus | globotriaosylceramide | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | cerebrovascular disease | - |
dc.subject.keywordPlus | clinical article | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | diagnostic accuracy | - |
dc.subject.keywordPlus | disease association | - |
dc.subject.keywordPlus | enzyme activity | - |
dc.subject.keywordPlus | Fabry disease | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | heart left ventricle hypertrophy | - |
dc.subject.keywordPlus | hemodialysis | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | kidney failure | - |
dc.subject.keywordPlus | Korea | - |
dc.subject.keywordPlus | maintenance therapy | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | mutational analysis | - |
dc.subject.keywordPlus | patient assessment | - |
dc.subject.keywordPlus | protein blood level | - |
dc.subject.keywordPlus | screening test | - |
dc.subject.keywordPlus | tandem mass spectrometry | - |
dc.subject.keywordPlus | Adult | - |
dc.subject.keywordPlus | Aged | - |
dc.subject.keywordPlus | alpha-Galactosidase | - |
dc.subject.keywordPlus | Fabry Disease | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Kidney Failure, Chronic | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Renal Dialysis | - |
dc.subject.keywordPlus | Trihexosylceramides | - |
dc.subject.keywordAuthor | End-stage renal disease | - |
dc.subject.keywordAuthor | Fabry disease | - |
dc.subject.keywordAuthor | Globotriaosylceramide | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.